Tactile Medical (TCMD) Q2 2026 earnings review
Profits Surge While AffloVest Stumbles
Tactile Medical delivered a mixed second quarter. While the core Lymphedema segment posted a solid 12% YoY gain, the previously high-flying Airway Clearance segment reversed course entirely, shrinking 7% YoY due to DME inventory dynamics. This divergence caused total revenue growth to decelerate to 9% (from 23% in Q1). However, profitability was a major bright spot: Gross margin expanded to 76%, and Adjusted EBITDA surged 49% to $11.4M. Management slightly lowered the top end of their full-year revenue guidance to reflect the AffloVest headwinds, but maintained their EBITDA target.
🐂 Bull Case
Gross margin expanded to 76%, and operating execution drove a 49% YoY increase in Adjusted EBITDA to $11.4M, proving the company can scale profitably.
Despite navigating a new Medicare prior authorization transition in April, the core Lymphedema business grew 12%, demonstrating the underlying strength of the transition to the NCD framework.
🐻 Bear Case
The AffloVest business went from a massive growth engine (averaging >50% growth in 2025) to a laggard (-7% YoY in Q2) due to DME inventory management.
Management trimmed the top end of their FY26 revenue guidance by $2M, acknowledging that the airway clearance disruption is a near-term reality.
⚖️ Verdict: ⚪
Neutral. The bottom-line execution is stellar, but the sudden collapse in Airway Clearance growth introduces near-term uncertainty that breaks the narrative of unbroken dual-segment momentum.
Key Themes
Airway Clearance Growth Abruptly Reverses
Directly contradicting the CEO's claim of 'strong momentum,' the Airway Clearance segment (AffloVest) reversed violently, dropping 7% YoY to $12.1M. This is a severe deceleration from 22% growth in Q1 and the 50-70% growth rates seen in 2025. Management blamed a 'temporary inventory management dynamic' among a few large DME providers associated with the launch of the next-generation AffloVest.
Revenue Guidance Trimmed
Due to the AffloVest inventory headwind, management lowered the top end of their FY26 revenue guidance from $368M down to $366M (growth of 9-11%, down from 9-12%). While the cut is small, it signals that the DME channel disruption is expected to linger into the second half of the year.
Medicare Prior Auth Impact Obscured
A new Medicare prior authorization requirement for pneumatic compression devices took effect on April 13, 2026. While Lymphedema grew 12% YoY, this is a notable deceleration from Q1's 23% growth. Q1 explicitly benefited from 'order acceleration' ahead of this regulatory deadline, making it difficult to gauge the true underlying organic demand versus administrative backlog resolution in Q2.
Lymphedema Core Generates Steady Growth
Despite the regulatory transitions, the Lymphedema segment remains stable, growing 12% YoY to $73.6M. This business continues to benefit from the Medicare National Coverage Determination (NCD) tailwind, which favors Tactile's higher-margin advanced Flexitouch system.
Operating Leverage is Delivering Returns
Management's shift from a heavy investment phase in 2025 to a focus on productivity is working. Operating expenses grew only 7% YoY, trailing the 9% revenue growth. Gross margins expanded to 76%, and Adjusted EBITDA accelerated by 49% to $11.4M.
Product Innovation & Strategic Partnerships
Tactile executed on two key product initiatives in Q2: They commercially launched the highly anticipated next-generation AffloVest system, and they secured an exclusive U.S. distribution agreement with ElastiMed for the MyoSleeve Wearable Compression Device, targeting the VA and DoD channels—a space management has historically viewed as a strategic, untapped market.
Other KPIs
Stable and expanding. Gross margin improved from 75% in Q2 2025 to 76% in Q2 2026, reflecting continued operating execution and product cost discipline.
Accelerating significantly from $3.2 million in the prior year quarter. EPS more than doubled to $0.34 per diluted share, up from $0.14.
The company holds zero debt and deployed $5.3 million to repurchase shares during Q2 under its ongoing $25.0 million share repurchase program, leaving $18.7 million in remaining authorization.
Guidance
Decelerating on the top end. The prior range was $360M - $368M. The updated guidance implies full-year YoY growth of 9% to 11%, driven by a more conservative outlook on DME ordering patterns for the Airway Clearance segment.
Stable. Management maintained their profitability guidance despite the trimmed revenue outlook, implying strong confidence in cost controls and operating leverage to protect the bottom line.
Key Questions
AffloVest Inventory Dynamics
How long do you anticipate the 'temporary inventory management dynamic' among DME providers to last, and what gives you confidence that this is purely an inventory transition rather than a loss of market share?
Medicare Prior Auth Transition
Now that we have a full quarter under the new Medicare prior authorization requirement, how has the transition impacted your actual order conversion times and referral-to-shipment ratios for Flexitouch?
MyoSleeve and the VA Channel
With the exclusive distribution agreement for ElastiMed's MyoSleeve, what is the timeline for this product to generate material revenue within the VA and DoD channels?